-
Product Insights
Hematopoietic Stem Cell Transplantation – Drugs In Development, 2023
Global Markets Direct’s, ‘Hematopoietic Stem Cell Transplantation - Drugs In Development, 2023’, provides an overview of the Hematopoietic Stem Cell Transplantation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hematopoietic Stem Cell Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TOS-358 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TOS-358 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TOS-358 in Solid Tumor Drug Details: TOS-358 is under development for...
-
Product Insights
Plasma Cell Neoplasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Plasma Cell Neoplasm - Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewNet Present Value Model: Cogent Biosciences Inc’s Bezuclastinib
Empower your strategies with our Net Present Value Model: Cogent Biosciences Inc's Bezuclastinib report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Idelalisib in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Idelalisib in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Idelalisib in Diffuse Large B-Cell LymphomaDrug Details:Idelalisib (Zydelig) drug belongs to...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cobimetinib Fumarate in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Soft Tissue Sarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Cobimetinib Fumarate in Soft Tissue Sarcoma Drug Details:Cobimetinib (GDC-0973 / RG7421...
-
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...
-
Product Insights
Multiple Myeloma (Kahler Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Myeloma Pipeline Products Market Report Overview Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. It mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain, and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery. The Multiple Myeloma Drugs in Development market research...